Better living through chemistry? A randomized, double-blind controlled study evaluating the efficacy of plaque control and gingival health impacts of a novel stannous fluoride-containing gel.


Journal

Journal of periodontology
ISSN: 1943-3670
Titre abrégé: J Periodontol
Pays: United States
ID NLM: 8000345

Informations de publication

Date de publication:
04 2023
Historique:
revised: 19 07 2022
received: 22 04 2022
accepted: 06 08 2022
pmc-release: 01 04 2024
medline: 26 4 2023
pubmed: 19 8 2022
entrez: 18 8 2022
Statut: ppublish

Résumé

Gingivitis is a nonspecific inflammatory lesion in response to the accumulation of oral biofilm and is a necessary precursor to periodontitis. Enhanced oral hygiene practices are necessary to reverse gingivitis and a dentifrice that could provide significant clinical reductions in plaque accumulation and gingival inflammation would be desirable to treat gingivitis and potentially prevent progression to periodontitis. This clinical study aimed to investigate the effect of a novel stannous fluoride-containing dentifrice with 2.6% ethylenediamine tetra-acetic acid (EDTA) as an antitartar agent to reduce Plaque Index (PI) and Gingival Index over a 3-month study period. This double-blind, randomized controlled clinical study evaluated plaque, gingival inflammation, and sulcular bleeding in patients using either a novel dental gel containing 0.454% stannous fluoride and 2.6% EDTA or a dentifrice with 0.24% sodium fluoride. Sixty subjects participated over a 3-month period. Co-primary endpoints were improvements in PI and Modified Gingival Index (mGI) from baseline values. No professional cleaning was performed during the study period. All subjects in the study demonstrated statistically significant improvements in all measures of oral hygiene over the 3-month study period. Subjects using the novel dental gel showed statistically significantly greater reductions in PI (ΔPI) [(-1.43 ± 0.34; -0.49 ± 0.13) (p < 0.00001)], mGI (ΔmGI) [(-1.11 ± 0.22; -0.16 ± 0.12) (p < 0.00001)], and modified sulcular bleeding index (ΔmSBI) [(-1.15 ± 0.18; -0.20 ± 0.07) (p < 0.00001)]. The novel dental gel demonstrated significant improvements in clinical parameters associated with gingivitis compared to a commercially available sodium fluoride dentifrice.

Sections du résumé

BACKGROUND
Gingivitis is a nonspecific inflammatory lesion in response to the accumulation of oral biofilm and is a necessary precursor to periodontitis. Enhanced oral hygiene practices are necessary to reverse gingivitis and a dentifrice that could provide significant clinical reductions in plaque accumulation and gingival inflammation would be desirable to treat gingivitis and potentially prevent progression to periodontitis. This clinical study aimed to investigate the effect of a novel stannous fluoride-containing dentifrice with 2.6% ethylenediamine tetra-acetic acid (EDTA) as an antitartar agent to reduce Plaque Index (PI) and Gingival Index over a 3-month study period.
METHODS
This double-blind, randomized controlled clinical study evaluated plaque, gingival inflammation, and sulcular bleeding in patients using either a novel dental gel containing 0.454% stannous fluoride and 2.6% EDTA or a dentifrice with 0.24% sodium fluoride. Sixty subjects participated over a 3-month period. Co-primary endpoints were improvements in PI and Modified Gingival Index (mGI) from baseline values. No professional cleaning was performed during the study period.
RESULTS
All subjects in the study demonstrated statistically significant improvements in all measures of oral hygiene over the 3-month study period. Subjects using the novel dental gel showed statistically significantly greater reductions in PI (ΔPI) [(-1.43 ± 0.34; -0.49 ± 0.13) (p < 0.00001)], mGI (ΔmGI) [(-1.11 ± 0.22; -0.16 ± 0.12) (p < 0.00001)], and modified sulcular bleeding index (ΔmSBI) [(-1.15 ± 0.18; -0.20 ± 0.07) (p < 0.00001)].
CONCLUSIONS
The novel dental gel demonstrated significant improvements in clinical parameters associated with gingivitis compared to a commercially available sodium fluoride dentifrice.

Identifiants

pubmed: 35980316
doi: 10.1002/JPER.22-0254
pmc: PMC10569749
mid: NIHMS1930049
doi:

Substances chimiques

Dentifrices 0
Sodium Fluoride 8ZYQ1474W7
Tin Fluorides 0
Edetic Acid 9G34HU7RV0

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-518

Subventions

Organisme : NCI NIH HHS
ID : P30 CA062203
Pays : United States
Organisme : NIBIB NIH HHS
ID : UH2 EB022623
Pays : United States

Informations de copyright

© 2022 American Academy of Periodontology.

Références

Compend Contin Educ Dent. 1997 Winter;18 Spec No:2-9
pubmed: 12206031
Am J Dent. 2020 Feb;33(1):3-11
pubmed: 32056408
J Stomatol Oral Maxillofac Surg. 2019 Jun;120(3):234-239
pubmed: 30763780
Periodontol 2000. 1997 Jun;14:33-53
pubmed: 9567965
J Clin Periodontol. 2017 Sep;44(9):866-871
pubmed: 28644512
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Evid Based Dent. 2007;8(3):74-5
pubmed: 17891122
Cochrane Database Syst Rev. 2019 Mar 04;3:CD007868
pubmed: 30829399
J Periodontol. 2003 Sep;74(9):1395-401
pubmed: 14584877
J Periodontol. 2021 Sep;92(9):1286-1294
pubmed: 33331040
J Clin Periodontol. 2007 Sep;34(9):762-7
pubmed: 17645550
J Periodontol. 2018 Jun;89 Suppl 1:S74-S84
pubmed: 29926944
J Dent Res. 1991 Nov;70(11):1431-5
pubmed: 1960253
J Periodontol. 1991 May;62(5):293-9
pubmed: 2072240
Periodontol 2000. 1994 Jun;5:78-111
pubmed: 9673164
J Periodontol. 2018 Aug;89(8):933-939
pubmed: 29644699
PLoS One. 2022 Jan 11;17(1):e0262118
pubmed: 35015771
J Periodontol. 2007 Jun;78(6):1011-6
pubmed: 17539713
PLoS One. 2016 Oct 24;11(10):e0164707
pubmed: 27776148
J Dent Res. 1988 Feb;67(2):503-7
pubmed: 11039067
J Am Dent Assoc. 2019 Apr;150(4S):S14-S24
pubmed: 30797255
J Periodontal Res. 1966;1:1-13
pubmed: 4224181
Dentistry (Sunnyvale). 2014 Jun 1;4(6):239
pubmed: 26052472
J Clin Dent. 2017 Sep;28(3):49-55
pubmed: 29211951
J Am Dent Assoc. 2018 Jul;149(7):576-588.e6
pubmed: 29957185
Dentistry (Sunnyvale). 2016 Oct;6(10):
pubmed: 28344856
J Clin Periodontol. 1998 Jul;25(7):536-41
pubmed: 9696252
BMC Oral Health. 2020 Mar 26;20(1):89
pubmed: 32216778
J Periodontol. 1981 Jan;52(1):30-4
pubmed: 6782227
J Dent Res. 2010 Jan;89(1):8-18
pubmed: 19918089
Dentistry (Sunnyvale). 2016 Oct;6(10):
pubmed: 28286702
J Dent Oral Sci. 2019 Dec;1(3):
pubmed: 31893264
J Am Dent Assoc. 2019 Apr;150(4S):S32-S37
pubmed: 30797257
Clin Exp Dent Res. 2016 Jan 28;2(1):6-17
pubmed: 29744145
Br Dent J. 2016 Nov 18;221(10):657-666
pubmed: 27857087
J Clin Dent. 1995;6 Spec No:54-8
pubmed: 8593194
J Periodontol. 1996 Jun;67(6):555-61
pubmed: 8794964
J Periodontol (1930). 1965 May-Jun;36:177-87
pubmed: 14296927
J Clin Periodontol. 1997 Jan;24(1):72-7
pubmed: 9049801
Indian J Dent Res. 2010 Apr-Jun;21(2):213-7
pubmed: 20657090
J Am Dent Assoc. 2006 Dec;137(12):1649-57
pubmed: 17138709
Lasers Surg Med. 2014 Sep;46(7):546-52
pubmed: 24916419
J Dent Res. 1974 Nov-Dec;53(6):1468-74
pubmed: 4154342
J Clin Periodontol. 2019 Dec;46(12):1205-1216
pubmed: 31562774
Dent Today. 1998 Jul;17(7):76-8, 80-2
pubmed: 9796462
Periodontol 2000. 2018 Feb;76(1):85-96
pubmed: 29193304
J Clin Periodontol. 2004 Apr;31(4):239-52
pubmed: 15016251
Periodontol 2000. 2005;37:35-47
pubmed: 15655024

Auteurs

Thair Takesh (T)

Beckman Laser Institute, University of California, Irvine, California, USA.

Arezou Goshtasbi (A)

Concorde College of Dental Hygiene, Garden Grove, California, USA.

Kairong Lin (K)

Beckman Laser Institute, University of California, Irvine, California, USA.

Susan Meishan Yang (SM)

Beckman Laser Institute, University of California, Irvine, California, USA.

Cherie Wink (C)

Beckman Laser Institute, University of California, Irvine, California, USA.
Concorde College of Dental Hygiene, Garden Grove, California, USA.

Maria L Geisinger (ML)

University of Alabama at Birmingham, Birmingham, Alabama, USA.

Petra Wilder-Smith (P)

Beckman Laser Institute, University of California, Irvine, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH